Insmed (NASDAQ:INSM) Director David Brennan Sells 25,000 Shares

Insmed, Inc. (NASDAQ:INSM) Director David Brennan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Insmed Trading Up 1.7%

Shares of NASDAQ:INSM opened at $129.41 on Friday. The company has a 50 day moving average of $117.76 and a 200-day moving average of $124.24. The firm has a market cap of $28.26 billion, a P/E ratio of -31.49 and a beta of 0.82. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The business had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. During the same period last year, the firm posted ($1.70) earnings per share. The business’s revenue was up 296.1% on a year-over-year basis. As a group, analysts anticipate that Insmed, Inc. will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the stock. iA Global Asset Management Inc. increased its position in shares of Insmed by 15,973.5% in the fourth quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock worth $4,644,000 after acquiring an additional 26,516 shares in the last quarter. Monashee Investment Management LLC acquired a new stake in shares of Insmed during the fourth quarter valued at approximately $8,702,000. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Insmed in the 4th quarter valued at approximately $3,562,000. Empowered Funds LLC lifted its position in shares of Insmed by 32.6% in the 1st quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after acquiring an additional 12,775 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in Insmed by 8,052.6% in the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock worth $21,493,000 after purchasing an additional 121,755 shares during the period.

Analyst Ratings Changes

INSM has been the subject of several research reports. Wells Fargo & Company raised their target price on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Evercore reiterated an “outperform” rating and issued a $170.00 price target on shares of Insmed in a research report on Friday, August 7th. BMO Capital Markets started coverage on shares of Insmed in a report on Monday, July 20th. They issued an “outperform” rating and a $192.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $235.00 price objective on shares of Insmed in a research report on Tuesday, July 28th. Finally, Guggenheim lowered their price objective on shares of Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $205.52.

About Insmed

Insmed Incorporated (NASDAQ: INSM) is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company’s work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed’s primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.